The emergence of new P2Y12 antagonists and ongoing uncertainties of platelet function testing dictate the need for larger RCT to answer these questions and investigate the clinical benefit of AP switching strategy in stroke patients based on MEA results. Here, P2RY12 is linked to Stroke.